** Shares of Starpharma Holdings fall as much as 2.2% to A$0.091, their lowest level since Sept. 11

** Biopharmaceutical co withdraws marketing authorisation application for SPL7013 nasal spray with Australia's Therapeutic Goods Administration

** SPL7013 is an antiviral spray for protection against COVID-19

** Co says withdrawal after a more than three-year application and review process that consumed significant internal resources

** About 1.5 mln shares change hands, 3 times the 30-day avg of 478,000 shares

** Starpharma down 45.9% YTD

(Reporting by Nikita Maria Jino in Bengaluru)

((Nikita.Jino@thomsonreuters.com;))